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Abstract 
Background: In some people with Parkinson’s disease (PD), α-synuclein (αSyn) accumulation may begin in the 
enteric nervous system (ENS) decades before development of brain pathology and disease diagnosis. 
Objective: To determine how different types and severity of intestinal inflammation could trigger αSyn accumu-
lation in the ENS and the subsequent development of αSyn brain pathology. 
Original Paper 
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Methods: We assessed the effects of modulating short- and long-term experimental colitis on αSyn accumulation 
in the gut of αSyn transgenic and wild type mice by immunostaining and gene expression analysis. To determine 
the long-term effect on the brain, we induced dextran sulfate sodium (DSS) colitis in young αSyn transgenic mice 
and aged them under normal conditions up to 9 or 21 months before tissue analyses. 
Results: A single strong or sustained mild DSS colitis triggered αSyn accumulation in the submucosal plexus of 
wild type and αSyn transgenic mice, while short-term mild DSS colitis or inflammation induced by lipopolysac-
charide did not have such an effect. Genetic and pharmacological modulation of macrophage-associated path-
ways modulated the severity of enteric αSyn. Remarkably, experimental colitis at three months of age exacer-
bated the accumulation of aggregated phospho-Serine 129 αSyn in the midbrain (including the substantia nigra), 
in 21- but not 9-month-old αSyn transgenic mice. This increase in midbrain αSyn accumulation is accompanied 
by the loss of tyrosine hydroxylase-immunoreactive nigral neurons. 
Conclusions: Our data suggest that specific types and severity of intestinal inflammation, mediated by mono-
cyte/macrophage signaling, could play a critical role in the initiation and progression of PD. 
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Introduction 
Parkinson’s disease (PD) is a progressively de-
bilitating neurodegenerative disease affecting 1% of 
the population above 60 years [1]. Typical symptoms 
are motor impairments including muscle rigidity, 
tremor, and bradykinesia. Neuropathologically, PD 
is hallmarked by loss of dopaminergic neurons in the 
substantia nigra (SN), a concomitant reduction of 
striatal dopaminergic signaling [2], and the presence 
of intraneuronal inclusions called Lewy bodies and 
neurites [3]. Lewy pathology is enriched in α-synu-
clein (αSyn), a presynaptic protein that tends to ag-
gregate and become phosphorylated at serine 129 
under pathological conditions [2]. Rare point muta-
tions in αSyn and gene multiplications also cause fa-
milial forms of PD and related neurological condi-
tions, and certain single nucleotide polymorphisms 
close to the αSyn gene (SNCA) locus are associated 
with increased risk for sporadic PD [4]. These find-
ings make αSyn a focal point of biomarker and drug 
development programs for PD. 
Several years before the first appearance of 
motor symptoms, many patients exhibit a variety of 
non-motor symptoms including constipation, sleep 
disorder, depression, and hyposmia [5–7]. Indeed, 
co-occurrence of some of these non-motor symp-
toms is coupled to elevated PD risk [8–11]. Constipa-
tion is an important non-motor feature of prodro-
mal PD, with 28-61% of patients having exhibited 
gastrointestinal dysfunction for several years during 
the prodrome [7,10,12]. Notably, αSyn-immunore-
active inclusions have been found in neurons of the 
submucosal plexus in people with PD [3,13]. Taken 
together, this converging evidence suggests an early 
involvement of the enteric nervous system (ENS) in 
the pathogenesis of PD. Already over a decade ago, 
Braak and colleagues hypothesized that αSyn-immu-
noreactive inclusions first appear in the ENS and 
then occur in the parasympathetic (e.g., vagal out-
put neurons in the intestines) and sympathetic (e.g., 
in the celiac ganglion in the upper abdomen) nerv-
ous system and gradually engage the brainstem, in-
cluding the vagal dorsal motor nucleus and midbrain 
areas [3,13]. Several studies in preclinical models 
have demonstrated that αSyn pathology in the gut is 
associated with the development of αSyn pathology 
in the brain [14–21]. For a better understanding of 
PD pathogenesis and particularly events happening 
at preclinical stages of PD, it is critical to determine 
factors that regulate αSyn accumulation in the ENS 
and to understand whether the process underlying 
αSyn accumulation in the gut can also lead to αSyn 
pathology in the brain. 
Inflammation can potentially trigger αSyn pa-
thology in the ENS of the gut and in the brain. A re-
cent finding in children with gastrointestinal inflam-
mation suggests an immune regulatory function of 
αSyn [22]. Immune pathways are indeed activated in 
the brain and colon of PD cases [23,24]. Also, several 
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genes associated with an increased PD risk have an 
immune system-related function [25], and it was re-
cently proposed that PD heritability is not simply 
due to variation in brain-specific genes, but that sev-
eral cell types in different tissues are involved [26]. 
Further genetic evidence supporting a role for im-
mune pathways in PD pathogenesis is provided by a 
genome-wide association study that identified com-
mon genetic pathways linking PD and autoimmune 
disorders [27]. Most prominently, LRRK2, a major 
genetic risk factor for PD [28] also confers increased 
risk for developing inflammatory bowel disease 
(IBD) [29]. Certain risk alleles are shared between PD 
and Crohn’s disease [30], and LRRK2 is known to 
modulate the function of monocytes, macrophages 
and other immune cells [31,32]. Intriguingly, IBD is 
associated with an increased risk for developing PD 
and specifically blocking the tumor necrosis factor 
(TNF) pathway reduces this risk [33–37]. Recently, it 
was reported that experimental colitis in αSyn trans-
genic mice leads to enteric accumulation of αSyn 
and the development of PD-like brain pathology and 
symptoms within a few months [38]. Converging 
clinical and nonclinical data suggest that the intesti-
nal immune environment plays a role in triggering 
PD or facilitating the molecular events involved in 
the earliest phases of the disease process [39,40]. 
Here, we tested the hypothesis that specific 
types and severity of intestinal inflammation are re-
quired to trigger the accumulation of αSyn in the 
ENS and the subsequent development of αSyn pa-
thology in the brain. Experimental forms of colitis in 
wild type and αSyn transgenic mice demonstrated 
that the type and degree of inflammation regulates 
the amount of αSyn accumulation in the colon. Mac-
rophage-related signaling limited the extent of αSyn 
immunoreactivity as demonstrated in a genetic and 
a pharmacological immune modulation paradigm in 
the experimental colitis mouse model. Most remark-
able, when αSyn transgenic mice were exposed to 
experimental colitis at 3 months of age and then 
were allowed to age normally up to 9 or 21 months, 
the accumulation of aggregated αSyn in midbrain, 
including the SN, was much exacerbated in the 21-
month-old group, but not in the 9-month-old group. 
These 21-month-old mice also exhibited loss of 
nigral tyrosine hydroxylase-immunoreactive neu-
rons. Together, our data provide experimental evi-
dence in mice that certain specific forms of intestinal 
inflammation might be a relevant upstream trigger 
that plays a critical role in the initiation of PD patho-
genesis and the disease progression. 
Methods 
Aim, design and setting 
We aimed to combine an αSyn transgenic 
mouse model of age-dependent development of 
αSyn pathology with well-established experimental 
colitis paradigms in order to explore the effect of 
type and severity of immune activation on the de-
velopment of αSyn pathology in the colon and the 
brain. The design and setting of the different studies 
are illustrated in Fig. 1. 
Mice 
Male C57BL/6J wild type mice (Jackson Labora-
tories, Bar Harbor, USA), hemizygous Tg(Thy1-
SNCA*A30P)18Pjk ((Thy1)-h[A30P]αSyn ) [41] and 
Tg(Thy1-SNCA*A30P)18Pjk crossed with 
Cx3cr1tm1Litt ((Thy1)-h[A30P]αSyn /Cx3cr1-def; ho-
mozygous for Cx3cr1-GFP knock-in allele; [42] trans-
genic mice were used for the study. (Thy1)-
h[A30P]αSyn transgenic mice express mutant hu-
man αSyn under the neuron selective Thy1 pro-
moter. (Thy1)-h[A30P]αSyn transgenic mice were 
crossed to Cx3cr1-def transgenic mice which express 
eGFP replacing fractalkine receptor gene expres-
sion. All mice were maintained on a C57BL/6J back-
ground for more than 10 generations and under spe-
cific pathogen-free conditions. To the extent possi-
ble, littermates were used in the experiments. 
Health status was monitored daily during experi-
ments. The in vivo experiments were endorsed by a 
Roche internal review board and approved by the lo-
cal animal welfare authorities of the Canton Basel-
Stadt, Basel, Switzerland. 
Experimental colitis paradigms in mice 
Paradigms for the induction of inflammation 
were either 1 week (acute) or 3-4 weeks (chronic) 
with or without an incubation phase under normal 
conditions of 2-, 6-, or 18-months post application 
(Fig. 1). Acute systemic inflammation was induced 
by intraperitoneal (i.p.) lipopolysaccharide (LPS) ap-
plication [43] of 0.5 mg/kg in 100 µl injection volume 
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Fig. 1 Age-dependent increase of intracellular αSyn accumulation in enteric nervous system of hemizygous (Thy1)-h[A30P]αSyn trans-
genic mice and setup of the experimental colitis paradigms. 
A Confocal microscopy imaging of the inclusions of human αSyn (red, antibody clone 211; human αSyn specific) within the ganglia of the 
submucosal plexus (green, peripherin; blue, DAPI/nuclei) of hemizygous (Thy1)-h[A30P]αSyn transgenic mice. Arrowhead points to one 
of the typical irregularly sized and shaped αSyn inclusion bodies visualized in 2D z-stacks of rotated confocal images. Scale bar: 100 μm.  
B Stereological quantification of normally occurring human αSyn inclusions in the myenteric and submucosal plexuses of 3- and 12-month-
old hemizygous (Thy1)-h[A30P]αSyn transgenic mice (n = 4 per group; mean and S.E.M. are shown; Student t-test between the two age 
groups in each region). C Setup of experimental colitis paradigms employing dextran sulfate sodium (DSS, per os in drinking water) or 
bacterial lipopolysaccharide (LPS, intraperitoneal injection). Except for the ‘chronic DSS paradigm, constant dose’, all paradigms were 
started at the age of 3 months. The ‘chronic DSS paradigm, constant dose’ was started in mice aged 5 months and the colon were analyzed 
right after. For some experiments, we used a ‘chronic DSS paradigm, increasing dose’, to mimic better the chronic nature of IBD and the 
longer water intervals are generally more gentle for the mice from an animal welfare perspective as well. Under this paradigm, we induced 
experimental DSS colitis intermittently as indicated over 23 days, then let the mice recover and age for two more months up to the age 
of 6 months on normal drinking water, and analyzed their colon. In a separate experiment, we aged the mice further up to 9 or 21 months 
and analyzed their brain pathology. Open arrows on time axis indicate that colon was analyzed and stars with closed arrows indicate that 
brains were analyzed. D Hematoxylin staining of 35 μm thick colon sections of 3-month-old hemizygous (Thy1)-h[A30P]αSyn transgenic 
mice. Organizational layers of the intact colon (left panel). Representative images of various severity degrees of DSS-driven colitis from 
weak leukocyte infiltration (top panel of acute DSS) to more extensive leukocyte infiltration with mucosal ulceration (lowest panel of 
acute DSS). Note the different appearance of enteric inflammation in acute LPS-driven peripheral inflammation compared with DSS, e.g., 
confined immune cell clustering and lymphoid hyperplasia, intact mucosal layer. Scale bar: 50 μm (intact colon), 100 μm (acute DSS), and 
200 μm (LPS).
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on day 0 and 3 (Sigma-Aldrich Chemie GmbH, Stein-
heim, Germany, LPS 055:B5). Acute colitis was in-
duced by application of 36-50kDa dextran sulfate so-
dium (DSS) [44] (160110, MP Biomedicals, LLC, Ill-
kirch, France) at 1%, 2.5% or 5% in autoclaved drink-
ing water for 5 continuous days respectively, fol-
lowed by 2 days of water (1 DSS application cycle). 
Chronic colitis was induced by two different dosing 
protocols: i) in a constant dose of DSS (1% or 2.5%) 
for 5 days and changed to 2 days with normal drink-
ing water and repeated three times (4 application 
cycles in total); ii) in an increasing dose of DSS start-
ing at 1% for 5 days followed for 4 days on normal 
drinking water, then increased to 1.5% DSS for the 
next 5 days followed by 4 days of water and a final 
cycle of 2% DSS followed by aging the mice on nor-
mal drinking water until they were sacrificed. Mice 
from the same littermate group were randomized 
per cage into ‘exposed to inflammation inducing 
agent’ (LPS or DSS, respectively) or ‘unaffected’ (ve-
hicle for the LPS paradigm or normal drinking water 
for the DSS paradigms, respectively). For the long-
term experiments with the two aging cohorts ‘9 
months’ and ‘21 months’, respectively, all mice in 
that study were simultaneously exposed in one large 
cohort at the age of about 3 months to the increas-
ing dose chronic DSS paradigm (Fig. 1) and DSS ex-
posure was stopped for all mice on the same day af-
ter the 23-day period. The mice were then kept and 
aged on normal drinking water and under normal 
housing conditions in the same room until the day 
they were perfused and tissue was collected. 
IL-10 treatment and exposure measurement 
Two different forms of mouse IgG bound mu-
rine IL-10 (mIgG(v1)-mIL10 and mIgG(v2)-mIL10) 
were diluted in pre-prepared sterile formulation 
buffer comprised of 0.5% mouse serum supple-
mented with 25 mM citrate, 300 mM arginine to a 
final concentration of 0.75 mg/ml and the pH ad-
justed to 6.7 on the day of application. Each mouse 
was treated once with 150 µg i.p. concurrently with 
the initiation of the acute colitis paradigm with 5% 
DSS. The concentrations of mIgG-mIL10 fusion pro-
teins in murine serum samples were determined by 
enzyme-linked immunosorbent assays (ELISA) spe-
cific for the Fab moiety of the administered mIgG-
mIL10 fusion protein. Biotinylated mIgG-mIL10-spe-
cific target molecules were used for capturing, goat 
anti-mIg IgG-HRP conjugate and peroxidase sub-
strate ABTS were used for quantitative detection of 
mIgG-mIL10 fusion proteins. 
Immunohistochemistry 
Mice were injected with a lethal dose of pento-
barbital (150 mg/kg). Upon full anesthesia, mice re-
ceived transcardial perfusion with room tempera-
ture phosphate buffered saline (PBS). For biochemi-
cal and immunohistochemical analysis, one section 
of the proximal colon was either fresh frozen and 
stored at -80°C or post-fixed in 4% paraformalde-
hyde (PFA) solution for 24 h. Following post-fixation, 
organs were incubated in 30% sucrose/PBS at 4°C 
for at least 48 h before further processing. Subse-
quently, enteric tissue was cryotome-sectioned to 
35 µm thick longitudinal sections (approx. 1 cm 
length). The brain was collected and post-fixed for 
24 h in 4% PFA followed by 30% sucrose in phos-
phate buffer until cryo-sectioning of floating sec-
tions at 40 μm. Histological analysis of mouse colon 
was performed using standard hematoxylin staining. 
Immunohistochemical staining was accomplished 
using the Vectastain Elite ABC Kits and Peroxidase 
Substrate Kit SK-4100 (Vector Laboratories, Burlin-
game, CA, USA) or fluorescently labelled secondary 
antibodies (Alexa 488, 555 or 647, Life Technologies, 
Zug, Switzerland). The following primary antibodies 
have been used for overnight incubation at a dilu-
tion of 1:1000; monoclonal antibody to human αSyn 
(clone 211, sc-12767, Santa Cruz Biotechnology, Hei-
delberg, Germany; specific to human αSyn and binds 
to normal αSyn as well as abnormal αSyn inclusions 
which contain the respective epitope), monoclonal 
antibody generated towards rat αSyn, cross-reactive 
with murine and human αSyn (Syn1/clone 42, BD 
Transduction Laboratories, Allschwil, Switzerland; 
used for wild type mice), polyclonal antibody to the 
peripheral neuronal marker Peripherin (Millipore 
Corporation, Billerica, MA, USA), and polyclonal an-
tibody to macrophage marker Iba-1 (Wako Chemical 
GmbH, Neuss, Germany). To detect αSyn phosphor-
ylated at Serine 129 (pSer129-positive inclusions of 
pathological/abnormal αSyn) in the free-floating 
brain sections, monoclonal antibody (ab51253, 
Abcam, Cambridge, USA) was used at a dilution of 
1:10000. Prior to the pSer129 staining, the free-
floating brain sections were incubated for 10 min at 
room temperature in a phosphate buffered saline 
solution containing 10 μg/mL proteinase K (Cat # 
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25530015; Invitrogen, California, USA). Tyrosine hy-
droxylase (TH)-immunoreactive cells were detected 
using a polyclonal antibody (657012, Millipore 
Sigma) at a dilution of 1:1000. To measure the den-
sity of Nissl-positive cells, the TH-stained cells were 
counter-stained with Cresyl violet. The slides were 
incubated in 0.1% Cresyl violet solution for 9 min 
and then dehydrated in 95% and 100% ethanol and 
then xylene prior to cover slipping with Cytoseal 60 
mounting media (Thermo Fisher Scientific). Quanti-
fications of the blind-coded TH/Nissl-stained slides 
were done using Stereo Investigator (version 
2017.01.1; MBF Bioscience, Williams, VT, USA) on an 
Imager M2 microscope (ZEISS) coupled to a com-
puter. We analyzed 5-7 nigral sections per animal, 
and a total of 7-8 animals per treatment group. We 
outlined the substantia nigra pars compacta and 
counted every TH-immunoreactive and Nissl-posi-
tive cell in that area (using a counting frame of 40 
µm x 40 µm, grid size of 140 µm x 140 µm, a guard 
zone of 2 µm and optical dissector height of 20 µm) 
and then computed the number of cells per section, 
generating the average cell count per animal. We 
then calculated the average count of cells per treat-
ment group and analyzed the data using unpaired 
Student’s t-test after confirming normality and ho-
moscedasticity in Prism 7.0 (GraphPad Software). 
Imaging and stereological quantification of αSyn 
deposits in enteric nervous system 
Imaging and stereological quantification were 
performed on a Zeiss Axio Imager Z2 fluorescence 
microscope (Carl Zeiss AG, Jena, Germany). Leica 
TCS SP5 confocal system using an HCX PL APO CS 40x 
1.3 oil UV or an HCX PL APO LB 63x 1.4 oil UV objec-
tive was utilized for image recording. Accumulation 
of αSyn in the ENS (i.e., punctate intracellular bod-
ies/features) was assessed on a random set of 3 ad-
jacent 35 µm thick, αSyn-immunostained sections 
comprising the myenteric and submucosal neuronal 
plexuses. Analysis was performed with the aid of a 
stereology software (Stereo Investigator 10, MBF Bi-
oscience, Williams, VT, USA) as described previously 
[45]. In the myenteric plexus ganglion, volume was 
defined by multiple outlined plexuses containing a 
range of 5-20 neuronal cells and quantified by the 
optical fraction fractionator technique. In contrast 
to the myenteric plexus, the submucosa consists of 
compact plexuses with 1-5 cells including intercon- 
necting neurites. Therefore, the entire submucosa 
was set as region of interest, analyzed with the area 
fraction fractionator technique. Results of the sub-
mucosal plexus are displayed by percent area con-
taining αSyn deposits. For the IL-10 experiment, 
αSyn positive inclusions from immunofluorescence 
images were counted for each image. Inclusion 
body-like features were filtered based on having a 
size between 12 and 50000 pixels and a minimal in-
tensity value greater than 300. The filtering step was 
performed to exclude small background features 
and macrophages (very large spots). The counts 
were then aggregated to the animal level by sum-
ming the inclusion feature counts of all images per 
animal and then normalizing for (i.e., dividing by) the 
number of images for a given animal. Upon explora-
tory data analysis two mice were excluded: one 
mouse because it only had one image (technical out-
lier, missing data point; repeating the staining for 
this one mouse would have required re-staining the 
entire cohort in order to be consistent with staining 
conditions for quantification; this was unnecessary 
after statistical analysis) and another due to it being 
an outlier, based on its infiltration score and image 
data (i.e., in contrast to the other mice that had re-
ceived DSS, this mouse did not show signs of inflam-
mation or colonic tissue damage that is normally in-
duced by DSS; it could not be determined if that 
mouse was correctly dosed with DSS and thus it was 
excluded from the analysis). 
Quantification of leukocytes infiltration 
To determine the leukocyte covered area in the 
colon after LPS or DSS application, three adjacent 
hematoxylin-stained sections were quantified. Total 
area of colon sections and localizations of leukocyte 
assemblies within the tissue architecture were iden-
tified and outlined utilizing a stereology software 
(Stereo Investigator 6, MBF Bioscience, Williams, VT, 
USA). Percentage of leukocyte covered area has 
been set in proportion to total area of the analyzed 
colon section, e.g., to at least the length of 1 cm of 
proximal colon. For the IL-10 experiment, hematox-
ylin-stained colon slices were examined by an expert 
pathologist blinded to treatment conditions. A score 
of 0-3 was assigned to each section for each of the 3 
layers lamina propria, submucosa and muscularis 
based on the degree of inflammatory infiltration. A 
score of 0 denoted no inflammation and a score of 3 
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indicated extensive infiltration. The mean of the val-
ues for all 3 layers was taken as the final measure of 
leukocyte infiltration per mouse. 
Quantification of Iba-1/αSyn-double positive 
macrophages 
The number of Iba-1/αSyn-double positive cells 
was evaluated by quantification of 10 random re-
gions in 2 adjacent sections of the proximal colon. 
The region of interest was set to contain the myen-
teric plexus/circular muscle layer and the submuco-
sal plexus. 
Scoring of pSer129 pathology and brain heatmap 
We evaluated pSer129 pathology on a full se-
ries of immunostained coronal sections from 10 
mice per treatment group (i.e., water vs. DSS-
treated groups) on blind-coded slides using a previ-
ously described method [46]. We visualized pathol-
ogy from one hemisphere of all brain sections (apart 
from the olfactory area) using a NIKON Eclipse Ni-U 
microscope and assigned scores ranging from 0 to 4 
to each brain area based on the relative abundance 
of proteinase K (PK)-resistant pSer129-positive in-
clusions (i.e., cell bodies and neurites). In this case, 
0 = no aggregates, 1 = sparse, 2 = mild, 3= dense, 4 = 
very dense. For the heatmap, we obtained the aver-
age score values of each brain area for each treat-
ment group. The average data for each treatment 
group (n=10 mice/group) was then represented as a 
heatmap in a sagittal mouse brain background. To 
create the brain heatmap a postscript file down-
loaded freely from Allen Brain Atlas (mouse, p56, 
sagittal, image 15 of 21; http://atlas.brain-
map.org/atlas?atlas=2#atlas=2&structure=771&res
olution=16. 75&x=%7755.7470703125&y=3899.625
&zoom=-3&plate=100883867&z=5 was converted 
to an XML in R v 3.4.4, and the mean scores were 
manually assigned to respective brain regions. The 
remaining brain regions were estimated via the R 
package ‘Akima’, using a pointwise bivariate inter-
polation algorithm for irregular data on the mean X 
and Y coordinates for each brain region. 
Densitometry of pSer129 αSyn brain pathology 
The density of pSer129 pathology in 12 major 
brain areas (reticular nucleus, pontine reticular nu-
cleus, periaqueductal gray, gray and white layer, re-
ticular formation, substantia nigra, ventral tegmen-
tal area, thalamus, hypothalamus, central amygdala, 
pallidum and striatum) was determined in the water 
and DSS-treated animals. A NIKON Eclipse Ni-U mi-
croscope was used to acquire 20x magnification im-
ages (without condenser lens) from all the indicated 
brain areas, using the same exposure time for all im-
ages. In all cases, images were acquired on three 
sections separated by 420 μm intervals (localized 
between Bregma). We then processed the acquired 
images using Image J64 [47], created a mask (to ex-
clude background) that redirects to the original im-
age for analysis, measured the total area and the 
mean grey value of the area that had inclusions. For 
brain areas such as periaqueductal gray that do not 
fill the entirety of the field to be analyzed, we drew 
a contour of the area and the analysis was per-
formed only within that contoured area. We subse-
quently calculated the grey value of the area per 
square pixels for each image (i.e., A.U./px2 = mean 
grey value x area stained/total area assessed). Based 
on this, we calculated the average grey value per 
square pixels for each brain area for each animal (n 
= 6 mice/group), and then extended this calculation 
to determine the average grey value per square pix-
els for each treatment group and each of the twelve 
brain areas of interest. 
Blinding of experimenters for histological and im-
munohistochemical analyses 
For analyses of colon and brain tissue on slides, 
a second individual assigned unique codes to stained 
slides. Therefore, the experimenter conducted the 
analyses blinded to the identity of the mice. For ran-
domization of treatment groups see above. 
mRNA expression 
To assess mRNA expression levels from the 
proximal colon, RNA was extracted from fresh fro-
zen tissue with MagnaLyser green beads (Roche Di-
agnostics, Mannheim, Germany) and Qiazol Lysis 
(Reagent cat.no.79306, Hilden, Germany) purified 
on MagnaPure LC (HP Kit no.03542394001, F. Hoff-
mann-La Roche AG, Rotkreuz, Switzerland) and am-
plified via real-time PCR (4 ng RNA/reaction; Light-
cycler 480, Roche Diagnostics Corporation, Indian-
apolis, USA). Amplification of mRNA was performed 
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by using TaqMan probes for human or murine spe-
cific α-synuclein and for selected cytokines/chemo-
kines (Applied Biosystems Europe B.V., Zug, Switzer-
land). Target mRNA was normalized to tissue spe-
cific murine GAPDH levels and displayed as relative 
expression after 30 amplification cycles. 
Statistics 
Measurements for inflammation and αSyn ac-
cumulation in the ENS were taken from distinct sam-
ples (e.g., in three to six technical replicates per 
mouse). Data from each mouse was used only once, 
thus no repeated measure of the same sample was 
performed. Statistical analysis of gut pathology and 
inflammation was performed using GraphPad Prism 
6.04 or 7.0 software (GraphPad Software, Inc. La 
Jolla, CA, USA). The results are expressed as mean 
values ± standard errors of the mean (S.E.M.). Stu-
dent’s t-test (or Welch’s t-test for unequal vari-
ances) was used to compare two groups and ANOVA 
was used for multi-comparison of groups followed 
by Tukey HSD post-hoc analysis. For the statistical 
analysis of the mRNA expression, data quality was 
assessed by inspecting the distribution of Cp values 
of reference endogenous genes across samples, by 
inspecting the level of Cp variation between tech-
nical replicates and by exploring the samples multi-
variate signal distribution as in a principal compo-
nent analysis. Relative gene expression levels were 
expressed as 2-(Cpgene – CpRef). Statistical analyses to as-
sess the effect of the experimental conditions on the 
log2 gene expression levels were done with linear 
models using the limma package (Bioconductor/R, 
[48]). These analyses were implemented in R v 3.1.1. 
For the statistical modelling of the effects of 
the IL-10 treatment on αSyn counts, as well as infil-
tration scores, the levels for IgG1(v1)-IL10 and 
IgG1(v2)-IL10 treatment were compared to the pos-
itive (vehicle/DSS) control. Additionally, since levels 
of the control antibody treatment (IgG1(v1)) were 
very similar to the positive control, the two groups 
were pooled in further contrasts in which effects of 
individual antibodies or control IgG was assessed. 
For αSyn counts in the enteric nervous system, a lin-
ear model on the treatment groups with one-degree 
freedom contrasts was applied. For the infiltration 
score a Kruskal-Wallis test, with the same contrasts, 
was used. All statistical tests were two-tailed with a 
significance level of p <0.05. 
For the statistical analysis of the pSer129 αSyn 
brain pathology, zero-inflated negative-binomial 
mixed-effects models with a random intercept for 
each sample and variance assumed to increase line-
arly with the mean (verified against a quadratic in-
crease using Akaike Information Criterion [AIC] and 
Bayesian Information Criterion [BIC]) were used to 
analyze the dataset via the ‘glmmTMB’ package in R 
v 3.4.4. Linear contrasts with false discovery rate 
(FDR) adjustments were then used to test our hy-
potheses and account for multiple testing (for brain 
area and experimental group). 
Results 
Experimental colitis exacerbates αSyn load in the 
submucosal plexus of αSyn transgenic and wild 
type mice 
During the process of further characterizing a 
(Thy1)-h[A30P]αSyn transgenic mouse line [41], we 
detected by immunohistochemistry human αSyn ac-
cumulation in all innervated organs that were ana-
lyzed (Suppl. Fig. 1). To examine the localization of 
αSyn inclusions in nervous structures in the ENS, we 
performed an immunofluorescent co-staining for 
human αSyn (clone 211) and peripherin, a specific 
marker for peripheral nerves. By applying confocal 
microscopy, we established a process and protocol 
to identify myenteric and submucosal plexuses in or-
der to quantify the αSyn inclusions found in the 
nerve cells of the ganglia in the colon. The intracel-
lular presence of the irregularly sized and shaped 
αSyn inclusion bodies was confirmed in 2D z-stacks 
of rotated confocal images (Fig. 1A). We observed 
an age-dependent (mice aged 3 months versus 12 
months) increase of baseline human αSyn inclusions 
in both plexuses (Fig. 1B). Given the clinical and epi-
demiological link between IBD and PD, we wanted 
to test whether different types and strengths of IBD-
related experimental inflammation in the colon ex-
acerbates this local accumulation of αSyn acutely 
(e.g., within a few days or weeks) and how the age 
of the αSyn transgenic mice may influence the out-
come. Administration of dextran sulfate sodium 
(DSS) in the drinking water in acute or chronic dosing 
paradigms are well-established mouse models of ex-
perimental colitis mimicking aspects of IBD, i.e., by 
exhibiting infiltration of leukocytes into the submu-
cosa with various degrees of destruction of the co-
lonic mucosa and submucosa [49]. It is well-known 
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that the effects induced by the DSS paradigm can 
vary substantially based on the genetic background 
of the mice and due to different animal housing en-
vironments. Thus, in order to establish the DSS par-
adigm in our environment and with our mice, we 
first tested the effect of DSS administration at differ-
ent doses and durations in the (Thy1)-h[A30P]αSyn 
transgenic mice (Fig. 1C). We observed that leuko-
cyte infiltration was appropriately modulated by the 
acute dose (1% or 2.5% DSS for 5 days followed by 2 
days drinking water) and chronic constant dose (1% 
or 2.5% DSS alternating with normal drinking water 
for 28 days, respectively) DSS paradigms (Fig. 1D and 
2A). In the same experiment, we wanted to test for 
an age effect on a potential aggravation of αSyn ac-
cumulation in the ENS and applied the acute dose 
paradigm on 3-month-old mice and the chronic dose 
paradigm was started at the age of 5 months leading 
to a final age of 6 months at analysis of the mice. In 
the acute DSS dosing paradigm with mice at the age 
of 3 months, 2.5%, but not 1%, DSS triggered intra-
cellular accumulation of αSyn in peripherin positive 
nerve cells of the submucosal plexus (Fig. 2A, B). In 
the 28-day chronic constant DSS dose paradigm in 
mice aged 6 months (Fig. 1C and 2A), we observed 
that the 1% constant chronic DSS dose showed a 
similar degree of αSyn inclusions as the 3-month-old 
mice which were on an acute 2.5% DSS dose para-
digm. In addition, mice previously exposed to 2.5% 
constant chronic DSS dose presented on average 
with a slightly but robust increased percent area of 
αSyn inclusions compared with the 6-month-old 
mice that were on 1% DSS (Fig. 2A). Together, this 
demonstrated that different DSS paradigms can be 
established in (Thy1)-h[A30P]αSyn transgenic mice 
and that different DSS paradigms can induce robust 
elevation of αSyn inclusions. This first experiment 
also provided us with data points to estimate a po-
tential effect size for triggering αSyn inclusions in 
the different DSS paradigms. We observed that the 
younger (Thy1)-h[A30P]αSyn transgenic mice 
showed a robust increase in αSyn inclusions and bet-
ter signal-to-noise conditions of the autofluorescent 
colonic tissue than the older ones, experiments 
were henceforth continued with mice of the 
younger age. In this initial experiment, it was also in-
teresting to observe that (Thy1)-h[A30P]αSyn trans-
genic mice exposed to acute 2.5% DSS colitis pre-
sented with several αSyn-positive cells with a mor-
phology consistent with them being infiltrating leu-
cocytes, which was confirmed by an Iba-1 co-stain-
ing (Suppl. Fig. 2). This finding was relevant for the 
quantification of αSyn inclusions in the myenteric 
and submucosal plexus, i.e., such features were ex-
cluded from the quantification process. 
Wild type mice also express endogenous αSyn 
in innervated organs, but at much lower levels com-
pared with the levels of human αSyn expressed by 
the hemizygous (Thy1)-h[A30P]αSyn transgenic 
mice (Suppl. Fig. 1). To confirm that the finding in 
(Thy1)-h[A30P]αSyn transgenic mice was independ-
ent of transgenic expression of human αSyn, we ap-
plied an acute 5% DSS dose paradigm (5 days DSS + 
2 days water) in wild type mice (Fig. 1C). We ob-
served, in the submucosal plexus, small inclusion 
bodies of endogenous murine αSyn (detected by ro-
dent cross-reactive αSyn-specific monoclonal anti-
body Syn1/clone 42, Fig. 2C, D). These features were 
close to undetectable in the water group that did 
not experience experimental colitis. A separate ex-
periment also confirmed that the observed effects 
of elevated αSyn inclusions following acute DSS (5% 
dose) could not be attributed to increased gene ex-
pression of murine or the transgenic human αSyn 
(Suppl. Fig. 3). Together, these results confirmed the 
validity of this experimental IBD paradigm to test the 
effect of inflammation on αSyn accumulation in the 
ENS in wild type and (Thy1)-h[A30P]αSyn transgenic 
mice. Because the (Thy1)-h[A30P]αSyn transgenic 
mouse model is well-established to analyze human 
αSyn-related pathology, we focused for the remain-
der of the study on employing these transgenic 
mice. 
Colitis induced by peroral DSS but not by in-
traperitoneal administration of LPS aggravates 
αSyn accumulation in colonic submucosal plexus 
of αSyn transgenic mice 
Different inflammatory agents induce different 
types of immune stimulation and thus can influence 
the phenotype of experimental colitis. A well-estab-
lished experimental immune trigger is the bacterial 
endotoxin LPS. In order to explore the effects of dif-
ferent approaches to induce inflammation in or 
nearby the gut in (Thy1)-h[A30P]αSyn transgenic 
mice, we compared the outcome of acute (5 days 
DSS + 2 days normal drinking water) 5% DSS per os 
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Fig. 2 Experimental DSS colitis severity and duration-dependent aggravation of accumulation of αSyn inclusions in the colonic submu-
cosal plexus of hemizygous (Thy1)-h[A30P]αSyn transgenic and wild type mice. 
A Administration of DSS in drinking water induced a robust increase of leukocyte infiltration in the acute (1% or 2.5% DSS for 5 days 
followed by 2 days of normal drinking water; one group was kept on normal drinking water) and chronic constant DSS dose (1% or 2.5% 
alternating with normal drinking water) paradigm in hemizygous (Thy1)-h[A30P]αSyn transgenic mice. The highest acute dose (2.5%) and 
the two constant chronic doses led to a very robust increase of αSyn inclusions in the submucosal plexus (stereological quantification of 
αSyn inclusions in the submucosal plexus of all 3- and 6-month-old hemizygous (Thy1)-h[A30P]αSyn transgenic mice; n = 5-7 per group; 
mean and S.E.M. are shown). B Representative 2D z-stacks of confocal images of increasing abundance of αSyn inclusions (red, human-
αSyn specific monoclonal antibody clone 211) in a ganglion of the submucosal plexus (green, peripherin) with cellular nuclei in blue (DAPI) 
in the acute DSS paradigm. Arrow heads point to the typical irregularly sized and shaped αSyn inclusion bodies that accumulate in the 
highest DSS dose. Scale bar: 200 µm. C Overview of colonic region of 3-month-old wild type mice exposed to water or acute DSS (5%) with 
immunofluorescence analysis of murine αSyn load in the colon performed immediately after colitis. White dotted rectangles in the top 
row indicate the area that was zoomed-in in the lower panels. In the zoom-ins we show representative images of DAPI and αSyn (red, 
rodent αSyn cross-reactive monoclonal antibody syn1/clone 42) inclusions with and without the peripherin channel (green). The white 
dotted circled area illustrates the peripherin-positive area that was analyzed for αSyn inclusion bodies (arrow heads in bottom row). Scale 
bar for the lower three panels: 200 μm. D Stereological quantification of murine αSyn inclusions in the submucosal plexus of wild type 
mice right after acute DSS colitis (n = 5 per group). Note the regularly arranged and smoothly distributed immunoreactivity for the physi-
ological αSyn with barely any inclusion bodies in the intact enteric nerves of the water group. For both panels (A) and (D), statistical 
analysis for αSyn accumulation was omitted as the noticeable and very robust differences between the means are self-evident (error bars 
indicate standard error of the mean) and an indication for an estimation for significance would be irrelevant.
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with acute 0.5 mg/kg intraperitoneal LPS admin-
istration (Fig. 1C and 3). To maximize the inflamma-
tory response, we administered both DSS and LPS at 
relatively high doses. At day 7, both agents had in-
duced variable degrees of leukocyte infiltration in 
the submucosa of the colon while a marked destruc-
tion of the mucosa was induced when giving only 
DSS (Fig. 1D). As before, the DSS-exposed mice pre-
sented with increased accumulation of αSyn in the 
ganglia of the submucosal plexus (Fig. 3A). In con-
trast, we detected no change in αSyn load in the 
myenteric plexus, consistent with lack of leukocyte 
infiltration in this part of the colonic wall (Fig. 3B). 
Despite the high dose, LPS-induced inflammation 
did not increase αSyn accumulation in the colonic 
nervous plexuses (Fig. 3C, D). Notably, LPS and DSS 
resulted in a differential expression of cytokines, 
and consistent with leukocyte recruitment, CCL2 
was elevated in both (Fig. 3F, G). In the LPS para-
digm, mRNA for IL-10 was markedly elevated, 
whereas DSS strongly increased IL-6 and also IL-1β 
but not IL-10. Together these results indicate that, in 
our model, colonic inflammation induced by peroral 
DSS but not intraperitoneal LPS increases the accu-
mulation of αSyn in the colon. 
Lack of monocyte/macrophage related Cx3cr1 
signaling during DSS colitis increases αSyn load in 
the submucosal plexus of αSyn transgenic mice 
Given the role of monocytes/macrophages in 
IBD and in the related DSS paradigm, we hypothe-
sized further that modulating monocytes/macro-
phages may affect accumulation of αSyn in our DSS 
model as well. In a first set of experiments we ma-
nipulated monocytes/macrophages genetically by 
crossing (Thy1)-h[A30P]αSyn transgenic mice with 
mice that have a deletion for the fractalkine recep-
tor Cx3cr1 (Cx3cr1-GFP knock-in mice) (Fig. 3A, B). 
The CX3CR1-CX3CL1 axis plays an important role in 
maintaining the function of the lamina propria mac-
rophage population of the gastrointestinal wall and 
lack of this signaling pathway in experimental colitis 
models may either aggravate or ameliorate the in-
duced pathology [50–52]. In our experiment, the 
area covered by infiltrating leukocytes following ex-
posure to DSS was near the mucosa and submucosa 
and was not significantly higher in the Cx3cr1-defi-
cient αSyn transgenic mice than in the Cx3cr1-com-
petent mice (Suppl. Fig. 3A). However, a signifi-
cantly higher level of αSyn accumulated in the sub-
mucosal plexus in αSyn transgenic mice lacking 
Cx3cr1 compared to αSyn transgenic mice express-
ing Cx3cr1 (p = 0.001, two-way ANOVA with Tukey 
HSD post-hoc analysis; Fig. 3A). In the myenteric 
plexus, we found no marked increase in αSyn accu-
mulation in neither the αSyn transgenic mice with 
normal Cx3cr1 nor the αSyn transgenic mice defi-
cient in Cx3cr1, indicating as in the experiments 
above a possible prominent role for the localization 
of leukocyte infiltration in the process of αSyn accu-
mulation in the submucosa (Fig. 3B). Collectively, 
our results in Cx3cr1-deficient αSyn transgenic mice 
provide a potential association between mono-
cyte/macrophage signaling and αSyn accumulation 
in ENS in this experimental IBD model. 
Systemic IL-10 reduces DSS-induced colitis and 
associated enteric αSyn accumulation in αSyn 
transgenic mice 
To continue testing the hypothesis that modu-
lating monocytes/macrophages may affect accumu-
lation of αSyn in our DSS model we moved to a phar-
macological modulation of this cellular subset. Inter-
leukin-10 (IL-10) is an important regulator of mono-
cytes/macrophages, and genetic ablation of IL-10 
signaling or blocking IL-10 with specific antibodies 
has been reported to enhance DSS colitis [53,54]. In 
the experiments with LPS we had also noted an in-
crease of IL-10 compared with the DSS paradigm and 
LPS inflammation was in contrast to DSS colitis not 
associated with increased αSyn accumulation in the 
ENS (Fig. 3). To mimic the effect of higher levels of 
IL-10 in an acute model of DSS colitis (5% DSS for 5 
days + 2 days normal drinking water, Fig. 1C), we ad-
ministered intraperitoneally recombinant murine IL-
10 (mIL10) in this paradigm. The half-life of injected 
recombinant IL-10 protein in blood is very short. To 
reduce the number of injections, we extended the 
half-life of mIL-10 in circulation by engineering it 
onto two different murine IgG variants (i.e., 
mIgG1(v1)-mIL10 and mIgG1(v2)-mIL10, respec-
tively). As described above, DSS induced a marked 
increase in leukocyte infiltration and αSyn accumu-
lation, and we found both to be similar in the un-
treated and control IgG treated group (Fig. 4A, B). In 
contrast, both mIgG1(v1)-mIL10 and mIgG1(v2)- 
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Fig. 3 Colitis induced by peroral DSS but not peritoneal LPS enhances αSyn accumulation in the colonic submucosal plexus of hemizy-
gous (Thy1)-h[A30P]αSyn transgenic mice and can be increased by lack of monocyte/macrophage-related Cx3cr1 signaling. 
Mice received in an acute paradigm either peroral 5% DSS in their drinking water or intraperitoneally 0.5 mg/kg LPS. Effects of DSS and 
LPS in the colon, respectively, were compared to effects induced by vehicle (see Figure 1C for timelines). Stereological quantification of 
αSyn inclusions in the submucosal plexus as % area (A, C) and in the mucosal plexus as particle load per ganglion (B, D) (Two-way ANOVA 
with Tukey post hoc test; covariates genotype and treatment paradigm). E Representative 2D stacks of confocal images of intracellular 
αSyn inclusions (red, human αSyn specific monoclonal antibody clone 211; arrow heads pointing to some selected inclusions) in a ganglion 
of the myenteric plexus (green, peripherin) with cellular nuclei in blue (DAPI). Scale bar: 50 μm. Gene expression analysis of selected 
cytokines in the colon of (Thy1)-h[A30P]αSyn transgenic mice that received either acute DSS (F) or LPS (G) compared to their respective 
vehicle or water controls. Note the strong increase in IL-6 and the lack of elevation of IL-10 in the DSS paradigm compared to the LPS 
paradigm indicating a different inflammatory colonic milieu despite the abundant leukocyte infiltration in both paradigms. N = 5-8 per 
group; mean and S.E.M.; Student’s t-test between inflammatory agent and vehicle for individual cytokines. 
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mIL10 significantly reduced leukocyte infiltration in 
mice treated with DSS (p<0.0001, one-way ANOVA 
with Tukey HSD post-hoc analysis; Fig. 4A, B). A sig-
nificant down-regulatory effect of an IL-10 treat-
ment on DSS colitis induced accumulation of human 
αSyn in the submucosal plexus was only observed 
with mIgG1(v2)-mIL10 (p=0.02, one-way ANOVA 
with Tukey HSD post-hoc analysis; Fig. 4B). This ef-
fect by mIgG1(v2)-mIL10 on αSyn levels was accom-
panied by detectable serum levels of mIgG1(v2)-
mIL10 at the end of the in vivo phase, whereas 
mIgG1(v1)-mIL10 was no longer detectable at that 
point (Fig. 4C). This indicates that although both 
forms of IL-10 have a down-regulatory effect on leu-
kocyte infiltration, a sustained pharmacological ex-
posure of IL-10 may be required for reducing αSyn 
accumulation. These results highlight an important 
role for the IL-10 pathway in keeping αSyn accumu-
lation at a reduced level throughout the course of 
experimental IBD. Together, our observations by ge-
netic (i.e., CX3CR1-CX3CL1 axis) and pharmacologi-
cal modulation (i.e., IL-10) of DSS colitis corroborate 
an important role for monocyte/macrophage path-
ways in the development of αSyn accumulation in 
the ENS of the colon. 
DSS colitis-induced submucosal αSyn accumula-
tion at a young age persists for months and is ex-
acerbated by lack of Cx3cr1 signaling 
In humans there is strong epidemiological evi-
dence that IBD increases PD risk [33,35,37] and re-
cent evidence in Crohn’s disease [55] indicates that 
such gut inflammatory conditions are associated 
with αSyn accumulation in the ENS [36]. In these ex-
periments in mice, we have until here established 
and replicated, in different setups, a link between 
modulation of inflammation and induction of αSyn 
accumulation in the ENS. Because longer exposure 
to DSS (i.e., over several weeks) mimics more closely 
the chronic nature of IBD, we elected to explore 
αSyn accumulation in the submucosal plexus of 
(Thy1)-h[A30P]αSyn transgenic mice that were sub-
jected to DSS colitis in a 4-week chronic increasing 
dose paradigm. In addition, the dose increase with 
longer water intervals is more gentle for the mice 
from an animal welfare perspective. In order to al-
low for a full recovery from the chronic inflamma-
tion, we aged the mice for two months on normal 
drinking water and analyzed them at the age of 6 
 
Fig. 4 Systemic IL-10 ameliorates DSS colitis and slightly re-
duces associated local αSyn accumulation in (Thy1)-
h[A30P]αSyn transgenic mice. 
Two different recombinantly engineered and murine IgG1-fused 
forms of murine IL-10 (mIgG1(v1)-mIL10 and mIgG1(v2)-mIL10) 
were administered (150 µg per mouse i.p.) at the beginning of 
the acute DSS paradigm (5%) in (Thy1)-h[A30P]αSyn transgenic 
mice. Vehicle and the mIgG1(v1) alone served as untreated con-
trols. A Leukocyte infiltration was assessed by visual scoring and 
(B) inclusion features of αSyn were stereologically and semi-au-
tomatically quantified and result log scaled for statistical analy-
sis. Both the vehicle group and the mIgG1(v1) group had similar 
levels of leukocyte infiltration and αSyn inclusions and were 
merged for the statistical analysis to compare with the IL-10 
treated groups. Both forms of IL-10 ameliorated leukocyte infil-
tration whereas mIgG1(v2)-mIL10 also blocked the appearance 
of αSyn inclusions significantly (n = 3-6 per group; mean and 
S.E.M.; one-way ANOVA and Tukey post hoc test). C Persistent 
exposure mIgG1(v2)-mIL10 versus mIgG1(v1)-mIL10 (lower limit 
of detection is indicated at <0.234 μg/ml) as measured in serum 
at the end of the in vivo phase corresponds with beneficial treat-
ment effects on αSyn readout observed above. The mIgG1(v1) 
was only measured in two mice.
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months (Fig. 1C). At this point we wanted again to 
explore the effect of modulating monocytes/macro-
phages in this chronic setting and added an experi-
mental arm with (Thy1)-h[A30P]αSyn transgenic 
mice lacking Cx3cr1. As expected, after 2 months of 
recovery, the area that is usually extensively cov-
ered by leukocytes in the submucosal plexus of the 
acute DSS paradigm had returned to normal levels 
following the two-month recovery period (Suppl. 
Fig. 4A). Remarkably, however, the area containing 
αSyn inclusions in the ganglia of the submucosal 
plexus was still almost doubled when compared to 
αSyn transgenic mice that were not exposed to DSS, 
and this was exacerbated in αSyn transgenic mice 
deficient for Cx3cr1 (Suppl. Fig. 4B). The finding in 
the αSyn transgenic mice suggests that accumula-
tion of αSyn is not a transient effect or response. In 
addition, modulation of monocytes/macrophages 
by down-regulating the CX3CR1-CX3CL1 axis con-
tributes to aggravation of this accumulation. 
Experimental DSS colitis-induced at a young age 
exacerbates αSyn brain pathology and dopamin-
ergic neuron loss in old αSyn transgenic mice 
At this point, we have established and repeat-
edly demonstrated that modulation of inflammatory 
mechanisms in experimental colitis induced by 
acute and chronic DSS administration is causatively 
linked to induction and persistence of intracellular 
αSyn inclusions in the ENS of young adult mice. The 
previously highlighted hypothesis by Braak and col-
leagues associates αSyn brain pathology in PD with 
αSyn pathology in the ENS earlier in life [3,56]. To 
assess development of brain αSyn pathology and to 
link it to IBD risk, we exposed 3-month-old hemizy-
gous (Thy1)-h[A30P]αSyn transgenic mice to a 
chronic increasing dose DSS paradigm or normal 
drinking water and after 23 days returned all mice to 
normal drinking water until sacrifice several months 
later (Fig. 1C). We chose to use the αSyn transgenic 
model rather than wild type mice for this study be-
cause of two reasons: 1) we knew that the model as 
hemizygous transgenic mice exhibit some αSyn 
brain pathology that develops slowly under baseline 
conditions. Importantly, the pathology is much less 
pronounced than in homozygous (Thy1)-
h[A30P]αSyn mice [57]; 2) at the time of the experi-
ment, it was not clear whether wild type mice could 
develop αSyn brain pathology upon DSS colitis. Thus, 
we chose hemizygous (Thy1)-h[A30P]αSyn trans-
genic mice to increase the chances for a successful 
outcome and potentially to aggravate the brain pa-
thology from mild to strong. After exposing the mice 
either to normal drinking water or a chronic increas-
ing dose DSS paradigm, we aged them in two co-
horts on normal water and housing conditions to ei-
ther up to the age of 9 months  or 21 months. At 
these two timepoints we analyzed various brain re-
gions for αSyn inclusions that are generally consid-
ered pathological by being proteinase K (PK)-re-
sistant and immunopositive for pSer129-αSyn. 
When we examined the 9-month-old αSyn trans-
genic mice, we found that both experimental groups 
(i.e., those who were on DSS and those who stayed 
on normal water throughout their entire life and 
thus never experienced DSS colitis) exhibited ex-
tremely low levels of pathological αSyn aggregation 
in the brain (Fig. 5 and Suppl. Fig. 5). Our observa-
tion of the level of pathological αSyn aggregations in 
the brain of these 9-month-old hemizygous (Thy1)-
h[A30P]αSyn transgenic mice (Fig. 5A) is indeed con-
sistent with earlier descriptions of the model at the 
age of 11 months [57]. The 21-month-old hemizy-
gous (Thy1)-h[A30P]αSyn transgenic mice that only 
received water during their lifetime showed, in con-
trast to the 9-month-old cohort, more discernible 
PK-resistant pSer129-αSyn immunoreactive fea-
tures (Fig. 5B) and the abundance of these features 
was consistent with previous observations in this 
transgenic line at the age of 24 months [57]. In 
marked contrast, the 21-month-old hemizygous 
(Thy1)-h[A30P]αSyn transgenic mice that were ex-
posed to DSS at three months of age presented with 
pSer129-positive αSyn pathology throughout vari-
ous brain regions in a much more exacerbated fash-
ion than mice that were aged up to 21 months with-
out having experienced DSS colitis at young age (Fig. 
5B-E). The degree and distribution of PK-resistant 
αSyn in the brain was similar to what was previously 
described for homozygous (Thy1)-h[A30P]αSyn 
transgenic mice at the age of 8 to 9 months [57]. The 
significant aggravation of αSyn pathology in the sub-
stantia nigra (p ≤ 0.01 in a negative-binomial mixed-
effects model adjusting for multiple comparisons 
performed over all brain areas) was accompanied by 
a significant loss of tyrosine hydroxylase (TH) and 
Nissl-positive cells at 21 months of age (p ≤ 0.05, Stu-
dent’s t-test; Fig. 6). Together, we found that exper- 
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Fig. 5 A 23-days chronic DSS colitis insult at young age causes an age-dependent accumulation of proteinase K-resistant pSer129-αSyn 
in various brain regions of (Thy1)-h[A30P]αSyn transgenic mice. 
A 23-days chronic increasing dose DSS paradigm was performed with 3-month-old (Thy1)-h[A30P]αSyn transgenic mice. After recovering 
and further aging, various brain regions were analyzed for proteinase K (PK)-resistant pSer129-αSyn immunoreactivity in 9-month (A) and 
21-month-old (B) mice, respectively. The dark brown features in (A) (barely any visible in both the water and the DSS group) and (B) 
(strongly visible with typical neuritic and punctated inclusion-type morphology) indicate PK-resistant inclusions with pSer129-αSyn immu-
noreactivity. Densitometric quantification of pSer129-αSyn immunoreactivity in different brain regions of 21-month-old mice (C, D) (n=6 
mice per group). In order to visualize better the differences between the water versus the DSS group at 21 months, brain regions with 
large increase were plotted on an y-axis up to 250 A.U./px2 and small increase on a y-axis up to 40 A.U./px2. The about <5 to 150 A.U./px2 
average values in the DSS group versus the about 0 to 30 A.U./px2 average values in the water group in several brain regions confirm the 
visual impression in panel (B). One 21-month-old mouse in the DSS group was excluded from analysis due to presumed failed treatment; 
it is included in the graphs. Statistical analyses were performed using negative-binomial mixed-effects models adjusting for multiple com-
parisons. E Representative heatmap of the average distribution scores of pSer129-αSyn immunoreactivity for each treatment group in 
varying brain regions in all the 9-month (A and Supplemental Figure 5) and 21-month-old (B) mice was generated in a sagittal mouse brain 
(n=10 mice per group). Statistical analyses were performed using linear mixed-effects model adjusting for multiple comparisons. A.U./px2, 
= mean grey value x area stained/total area assessed. Scale bars: 500 μm.
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imental DSS colitis at a young age caused an age-de-
pendent exacerbation of PK-resistant pSer129-αSyn 
pathology and a loss of nigral dopaminergic neurons 
in the brains of (Thy1)-h[A30P]αSyn transgenic mice. 
Discussion 
Currently, there is no therapy for PD available 
to slow or stop disease progression and an obstacle 
in the quest to develop one is that we do not under-
stand how the disease develops [58]. Abnormal in-
traneuronal accumulation of αSyn (i.e., in Lewy bod-
ies and neurites) is a key neuropathological hallmark 
and the distribution of Lewy pathology in postmor-
tem brain is used for staging in PD [2,59]. Accumula-
tion of αSyn has also been observed in the periph-
eral nervous system in PD, some individuals at risk 
of developing the disease, and normal individuals 
[60–62]. Similar to this finding in humans, αSyn-im-
munoreactive inclusions and signs of age-dependent 
αSyn-related pathological changes have also been 
detected in the ENS of wild type rats [63,64] and sev-
eral transgenic mouse models prior to development 
of brain pathology [21,65]. Based on preclinical 
models employing injection of brain extracts or re-
combinant αSyn fibrils to different brain regions and 
intestines [15–17,19,20,46,66,67] together with 
postmortem brain pathology [56,59,68], it has also 
been suggested that αSyn pathology propagates 
temporospatially from cell-to-cell in a prion-like 
manner [3,59,66,68,69]. However, the initial factors 
triggering αSyn aggregation in the tissue or organ of 
origin of the pathology are yet to be established [58] 
and the involvement of peripheral stimuli in the ag-
gregation and pathogenic spread of αSyn is only be-
ginning to unravel. 
In this study, we provide evidence that DSS co-
litis, i.e., an experimental IBD-like inflammation, 
triggers αSyn accumulation in the ENS of wild type 
mice and in a human αSyn transgenic mouse model 
of PD (Fig. 2). We found aggravation of enteric αSyn 
accumulation in αSyn transgenic mice lacking Cx3cr1 
signaling and amelioration of inflammation and as-
sociated slight reduction of enteric αSyn load by sys-
temic IL-10, demonstrating that genetic and phar-
macologic modulation of inflammation can influ-
ence the degree of αSyn accumulation in the ENS 
(Fig. 3 and 4). 
 
 
Fig. 6 A 23-days chronic DSS colitis insult at young age results in loss of tyrosine hydroxylase- and Nissl-positive cells in the substantia 
nigra of (Thy1)-h[A30P]αSyn transgenic mice at 21 months of age. 
(Thy1)-h[A30P]αSyn transgenic mice were exposed to a 23-days chronic increasing dose DSS paradigm at the age of 3 months followed by 
aging on normal drinking water up to the age to 21 months. These mice showed a significant loss of mean count of Nissl-positive cells 
with tyrosine hydroxylase (TH) immunoreactivity and cellular Nissl staining in the substantia nigra compared to age-matched littermate 
mice in the group that did not experience DSS colitis (water). A Representative images of two levels of the substantia nigra in one mouse 
per group. B Stereological quantification of cells positive for TH or Nissl (n=7-8 mice per group). Statistical analyses of the TH dataset were 
performed using Student’s t-test, while Welch’s t-test was used for the Nissl dataset to adjust for unequal variances. Scale bar: 500 μm.
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Because IL-10 and the CX3CR1-CX3CL1 axis are able 
to mediate this effect, this suggests that mono-
cytes/macrophages may modulate the process in 
this model. We further observed that the aggra-
vated αSyn accumulation in the ENS persisted even 
after two months of recovery from DSS colitis and 
was aggravated in the absence of CX3CR1 signaling. 
This indicates that the accumulation is persistent 
and this further establishes that monocytes/macro-
phages play a critical role in this process (Suppl. Fig. 
4). Remarkably, at 18 months but not 6 months post 
induction of DSS colitis (thus, at age 21 months but 
not 9 months, respectively), αSyn transgenic mice 
had developed massively elevated αSyn brain pa-
thology (Fig. 5 and Suppl. Fig. 5). This elevated PK-
resistant pSer129-αSyn pathology in the midbrain, 
including the substantia nigra, and other brain re-
gions coincided with an average decrease of 30-50% 
of TH- and Nissl-positive cells in the nigra (Fig. 6). We 
chose to perform the long-term experiments in αSyn 
transgenic mice rather than wild type mice while be-
ing aware of the caveats of employing genetic over-
expression models, which use a neuron selective 
Thy-1 promoter cassette such as these (Thy1)-
h[A30P]αSyn transgenic mice. However, these par-
ticular αSyn transgenic mice had previously been 
shown to slowly develop αSyn pathology in the brain 
on a homozygous genotype [41,57] making them 
ideal when asking the question of whether transient 
colonic inflammation can aggravate brain pathology 
in a genetically predisposed animal such as the hem-
izygous transgenic mice used in this study. Others 
have recently demonstrated in a more aggressive 
αSyn transgenic mouse model that mild DSS colitis 
can accelerate αSyn accumulation in the ENS and 
brain [38]. In future long-term studies, we plan to 
address whether αSyn pathology develops also in 
the brains of wild type mice if they sustain transient 
experimental IBD at a young age. In our present 
study, experimental DSS colitis in αSyn transgenic 
mice recapitulated the accumulation of enteric αSyn 
which is proposed to occur in humans several years 
before PD diagnosis [39]. Additionally, the subse-
quent age-related development of αSyn pathology 
in the brain of αSyn transgenic mice together with 
the loss of nigral dopaminergic neurons mimicked a 
progression of the disease similar to what is consid-
ered to occur in PD. 
We established that a mechanism by which a 
specific type of peripheral inflammation promotes 
αSyn accumulation in the colon potentially involves 
monocytes and macrophages. Both peroral DSS and 
intraperitoneal LPS administration provoked strong 
local immune reactions resulting in leukocyte infil-
tration into the submucosa of the colon. The in-
flamed region of the colon contains the submucosal 
plexus and is anatomically separated from the 
myenteric plexus by a thick circular muscle (Fig. 1). 
This discrete localization of inflammation to the sub-
mucosa might explain why αSyn only accumulated 
in the nerves of the submucosal plexus and not in 
the myenteric plexus of our mice that received DSS 
in both a strong acute and the two chronic para-
digms. The mechanism underlying how intraperito-
neally administered LPS leads to submucosal leuko-
cyte infiltration likely involves the monocyte attract-
ant chemokine CCL2 (Fig. 3), but the specifics remain 
to be clarified [70]. Indeed, CCL2 was also upregu-
lated in the colon of our DSS model. However, in 
contrast to intraperitoneal LPS, where infiltrating 
macrophages were present in discrete patches in 
the colonic wall, DSS-related macrophage infiltra-
tion was distributed both in small groups and larger 
randomly distributed patches of cells across the en-
tire colonic submucosa. Also, perorally administered 
DSS destroys the mucosa of the colon, similar to 
some forms of ulcerative colitis, resulting in the tran-
sient disintegration of the intestinal epithelial bar-
rier. In our (Thy1)-h[A30P]αSyn transgenic mice, the 
subsequent immune response to the infiltration of 
commensal bacteria evoked an elevated expression 
of cytokines such as IL-1β and IL-6, a phenomenon 
also observed in the colon of IBD patients [71,72]. 
This upregulation was absent in the LPS paradigm in 
which the intestinal mucosa remained intact. By act-
ing on tight junctions, IL-1β and IL-6 can increase in-
testinal barrier permeability (gut leakiness), facilitat-
ing the recruitment of additional immune cells to 
the site of the inflammation, eventually culminating 
in widespread immune activation [73,74]. Con-
sistent with the breach of barrier permeability in our 
mouse model, some PD patients exhibit increased 
colonic cytokines such as IL-1β, IL-6 and TNF, occur-
ring together with increased intestinal permeability 
[23,75]. In this context, it is also notable that people 
with Crohn’s disease present with increased enteric 
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αSyn expression [55] and even more striking that 
IBD patients on anti-TNF therapy have a reduced risk 
of developing PD compared to IBD patients not 
given this treatment [35]. Notably, mucosal macro-
phages with intra-lysosomal αSyn content were pre-
viously described in the intact human appendix [76]. 
These macrophages were in close proximity to the 
axonal varicosities of the vermiform appendix, 
which showed an enriched staining for αSyn in the 
mucosal plexus. Furthermore, we recently found 
that the vermiform appendix contains aggregated 
and truncated αSyn that has the propensity to seed 
aggregation of recombinant αSyn in vitro [62]. Our 
finding of LPS not being able to induce an αSyn phe-
notype in the colon is in contrast to the reports by 
Kelly and colleagues who injected wild type mice 
with LPS and observed an immediate and progres-
sive increase in αSyn immunoreactivity in the myen-
teric ganglia of the large intestine but not in the 
small intestine [77]. The low dose (0.5 mg/kg used in 
our study versus 2.5 mg/kg used by Kelly and col-
leagues), coupled with the possible usage of differ-
ent bacterial strains to generate LPS affecting po-
tency and pyrogenicity of LPS (here strain O55:B5 
was administered versus presumably strain O111:B4 
used by Kelly and colleagues and others [78]), and 
potential effects of different environments and mi-
crobiomes [79] may contribute to this discrepancy. 
It will be interesting to study the mentioned param-
eters and their role in inducing αSyn pathology fur-
ther in rodent models and explore how this could be 
translated to the even more heterogeneous human 
setting. Similarly, others showed that employing a 
sub-chronic 0.5% DSS paradigm for 3 weeks in wild 
type mice did not trigger an αSyn pathology in the 
colon [80]. While we have not tested this particular 
sub-chronic DSS colitis paradigm and instead had ad-
ministered 5% DSS acutely to the wild type mice (Fig. 
2C), the data by Garrido-Gil and colleagues may cor-
roborate our results which show in αSyn transgenic 
mice that a certain DSS dose and severity of inflam-
mation is required in order to induce accumulation 
of αSyn in the submucosal plexus (Fig. 2A). 
What could be a functional role of the αSyn 
species found in abundance in the gut wall? Mono-
meric and oligomeric αSyn species reportedly act as 
chemoattractants for neutrophils and monocytes, 
enhancing the maturation of dendritic cells in the 
ENS [22,81]. With such a role in intestinal immunity, 
it is possible that the tissue destruction induced by 
DSS in the present study led to release of αSyn, 
which perhaps served as a chemoattractant for 
monocytes. The increased abundance of αSyn and 
altered intestinal permeability, along with the DSS-
evoked inflammatory response may have provided 
an enabling milieu allowing further αSyn accumula-
tion in the ENS of the colon [77]. Macrophages and 
other immune cells are also regulated by several 
genes including LRRK2, an established risk gene for 
PD and IBD. It will be interesting to explore how mu-
tations in genes that control autophagy, including 
the LRRK2 gene, influence the handling of αSyn by 
macrophages that invade the inflamed colon in our 
DSS colitis paradigm. Despite the intriguing transla-
tional aspect of our finding in the DSS paradigm, oth-
ers have very recently reported that DSS colitis in 
mice down-regulates the expression of enteric αSyn 
on protein levels in vivo [82,83]. This is in contrast to 
our immunofluorescence (i.e., increased accumula-
tion of αSyn in submucosal plexus upon DSS colitis; 
Fig. 2, 3, and 4) and gene expression data (e.g., no 
change in endogenous and transgenic αSyn upon 
DSS colitis; Suppl. Fig. 3) in the same paradigm and 
may reflect the well-known lab-to-lab variability 
that can occur for the DSS models [84]. 
Perhaps the most striking finding in our study 
was that a single period of DSS-induced colitis at a 
young age led to an exacerbation of αSyn pathology 
in the brain of αSyn transgenic mice much later in 
life (Fig. 5). How does severe αSyn inclusion pathol-
ogy develop in the brains of these mice? One hy-
pothesis is that the brain αSyn pathology observed 
in this study could be due to direct effects of periph-
eral immune activation on the brain and that certain 
peripheral triggers can directly affect microglial ac-
tivity. For instance, short-chain fatty acids derived 
from gut microbiota appear to influence function 
and maturation of microglia in the mouse brain [85] 
and inflammatory mediators released by gut micro-
biota into the bloodstream have been suggested to 
induce brain pathology and behavioral changes in an 
αSyn transgenic mouse model [86]. Moreover, rats 
and nematodes have been reported to develop αSyn 
inclusions after exposure to the bacterial amyloid 
protein curli, a protein which stimulates micro-
gliosis, astrogliosis, and secretion of IL-6 and TNF 
[87]. Intriguingly, a recent study reported that pe-
ripherally applied inflammatory stimuli induce acute 
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immune training (that exacerbates β-amyloid pa-
thology) and immune tolerance in the brain that re-
programs microglia, an effect which can persist for 
at least six months [88]. Whether this is a relevant 
mechanism in the DSS paradigm needs to be ex-
plored. 
Another hypothesis is that the observed brain 
αSyn pathology may have accumulated as a conse-
quence of the transfer of pathogenic αSyn seeds 
from the gut via the vagal nerve. Several experi-
mental studies have demonstrated that pathogenic 
αSyn seeds can be transferred from the peripheral 
to the central nervous system. Aggregated recombi-
nant αSyn injected intraperitoneally, intramuscu-
larly or into the gastric wall of certain mouse models 
of PD results in αSyn inclusions in the brain [16,89]. 
Data from animals injected with recombinant αSyn 
protein in the gut wall or viral vectors expressing 
αSyn into the vagal nerve suggest that pathogenic 
seeds can be transmitted via the vagal nerve 
[15,19,20,64,67,90–92]. A role for the vagal nerve in 
PD was also suggested by an epidemiological study 
indicating that vagotomy in a Danish population is 
associated with decreased PD risk [93], although this 
association has been challenged [94]. In the present 
study, αSyn pathology was much more prominent in 
the reticular nucleus (including the vagal nucleus) 
and midbrain areas compared to the rostral areas at 
18 months post DSS colitis. Although we did not con-
duct the definitive experiment of cutting the vagal 
nerve, our data are consistent with the growing 
body of evidence that the vagal nerve is involved in 
the accumulation of αSyn aggregates in the brain. 
That said, the innervation of the colon occurs via 
both parasympathetic (e.g., vagal output neurons) 
and sympathetic (e.g., in the celiac ganglion of the 
upper abdomen) nerves. The possibility of propaga-
tion of αSyn pathology via the two routes is sup-
ported by the observation that injection of recombi-
nant αSyn fibrils to the duodenum of certain αSyn 
transgenic rats leads to accumulation of pathologi-
cal αSyn in organs innervated by the parasympa-
thetic and the sympathetic nerves [67] and an age-
dependent propagation of αSyn pathology from gut-
to-brain in wild type rats [64]. Clinically, more rele-
vant, αSyn accumulation is present in both parasym-
pathetic and sympathetic vagal nerves in humans as 
well [95]. Thus, propagation may occur through both 
vagal and spinal routes. 
Aging is considered a major risk factor for neu-
rodegenerative diseases, as failing cellular mecha-
nisms are proposed to be unable to efficiently clear 
pathologically accumulating proteins and organelles 
[96]. Intriguingly, in the current study, while both co-
horts were exposed to the same peripheral DSS co-
litis insult at 3 months of age, αSyn pathology only 
developed in the brain of aged (21-month-old) but 
not in the relatively younger (9-month-old) mice 
(Fig. 5). While the mechanisms involved in this phe-
nomenon are still unclear, a recent study in mice re-
ports an age-dependent association of development 
of αSyn pathology in the brain and development of 
motor deficits after inoculating the gut wall with re-
combinant αSyn fibrils [20]. Investigating this fur-
ther, the study observed a reduction of the lysoso-
mal enzyme glucocerebrosidase in the gut of aged 
but not young mice [20]. Viral vector-based overex-
pression of glucocerebrosidase partially rescued the 
ENS network connectivity with concomitant variable 
downregulation of pSer129-αSyn levels [20]. Alt-
hough other age-related factors are likely involved, 
the finding of Challis and colleagues, together with 
the well-known genetic risk for glucocerebrosidase 
and several other lysosomal genes in PD [97,98], 
suggest a critical role of the lysosomal pathway in 
the long-term persistence of pathology in the ENS 
and the progression of αSyn pathology from the gut 
to the brain of aged mice. Upcoming studies in hu-
man tissue may shed more light on the mechanisms 
on how autophagy-lysosomal pathways are regu-
lated and how they, together with aging, may con-
tribute to the pathogenesis in PD. 
In summary, we report that αSyn accumulates 
in the colon of αSyn transgenic and wild type mice 
subjected to experimental DSS colitis and that this 
process can be modulated by genetically and phar-
macologically modifying pathways related to mono-
cyte/macrophage signaling. We further demon-
strate that chronic but transient DSS colitis in young 
αSyn transgenic mice leads to a markedly exacer-
bated accumulation of αSyn aggregates in the brain 
of aged mice. In the same aged mice, the numbers 
of TH- and Nissl-positive neurons in the substantia 
nigra are reduced, suggestive of a neurodegenera-
tive process. Together, our findings are in conso-
nance with studies demonstrating a link between 
IBD and PD [33,35,99] and suggest a critical role for 
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specific types of intestinal inflammation and αSyn 
accumulation in the initiation and progression of PD. 
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